TOP - August 2017, Vol 10, No 3

The United States may be in the midst of an opioid epidemic, but the undertreatment of pain remains an issue for patients with cancer.
Although the 5-year survival rate for multiple myeloma is less than 50%, this type of cancer has witnessed a resurgence of drug therapies.
The Oncology Pharmacist (TOP) spoke with Steve Stricker, PharmD, MS, BCOP at the 2017 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference about the importance of provider status, why clinical oncologists may be overlooked by their peers, and the most fulfilling part of his work.
Childhood cancer therapy can be a double-edged sword; it often leads to a cure, but long after treatment ends, some survivors have treatment-related side effects.
Here's what you can expect to find in the August issue of The Oncology Pharmacist.
Each year, >200,000 individuals in the United States are diagnosed with a primary or metastatic brain tumor. Primary brain tumors comprise approximately 40,000 of these diagnoses.
The power to fight a virtually infinite array of pathogens is one of the hallmarks of the human immune system, and random diversity is its secret weapon.
Adding the investigational drug indoximod, an indoleamine 2,3-dioxygenase (IDO) pathway inhibitor, to the checkpoint inhibitor pembrolizumab led to higher response rates in patients with advanced melanoma than what is reported with pembrolizumab monotherapy,
Although transplantation offers cures or durable remissions for malignancies, relapse is a frequent occurrence in many diseases, and remains a major cause of mortality.
Despite significant progress in stem-cell transplantations over the past decade, graft-versus-host disease (GVHD) remains the leading cause of nonrelapse death in this patient population.
Page 1 of 2
Results 1 - 10 of 20